Algorae Pharmaceuticals Ltd Total Assets
Algorae Pharmaceuticals Ltd total assets. Based on the latest financial reports, Algorae Pharmaceuticals Ltd (1AI) holds total assets worth AU$2.00 Million AUD (≈ $1.42 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 1AI market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Algorae Pharmaceuticals Ltd (2004–2025)
Total assets of Algorae Pharmaceuticals Ltd from 2004 to 2025. This chart illustrates how Algorae Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See 1AI share price today for real-time trading data and today's change.
Algorae Pharmaceuticals Ltd - Asset Composition Analysis
Algorae Pharmaceuticals Ltd Total Assets Breakdown (June 2025)
Algorae Pharmaceuticals Ltd total assets breakdown as of June 2025. Algorae Pharmaceuticals Ltd's total assets of AU$2.00 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 19.6% |
| Accounts Receivable | AU$40.57K | 1.7% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Algorae Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Algorae Pharmaceuticals Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Algorae Pharmaceuticals Ltd's current assets represent 100.0% of total assets in 2025, an increase from 48.2% in 2004.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2025, down from 37.1% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Algorae Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Algorae Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Algorae Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.99 | 17.41 | 9.13 |
| Quick Ratio | 17.99 | 17.41 | 9.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$1.89 Million | AU$2.39 Million | AU$2.17 Million |
Algorae Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Algorae Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.78 |
| Latest Market Cap to Assets Ratio | 5.37 |
| Asset Growth Rate (YoY) | -56.3% |
| Total Assets | AU$2.40 Million |
| Market Capitalization | $12.88 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Algorae Pharmaceuticals Ltd's assets at a significant premium (5.37x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Algorae Pharmaceuticals Ltd's assets decreased by 56.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Algorae Pharmaceuticals Ltd (2004–2025)
The table below shows the annual total assets of Algorae Pharmaceuticals Ltd from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.40 Million ≈ $1.70 Million |
-56.33% |
| 2024-06-30 | AU$5.49 Million ≈ $3.89 Million |
-11.90% |
| 2023-06-30 | AU$6.23 Million ≈ $4.41 Million |
+45.87% |
| 2022-06-30 | AU$4.27 Million ≈ $3.02 Million |
+160.27% |
| 2021-06-30 | AU$1.64 Million ≈ $1.16 Million |
-51.57% |
| 2020-06-30 | AU$3.39 Million ≈ $2.40 Million |
-41.12% |
| 2019-06-30 | AU$5.76 Million ≈ $4.08 Million |
-24.30% |
| 2018-06-30 | AU$7.61 Million ≈ $5.38 Million |
-12.49% |
| 2017-06-30 | AU$8.69 Million ≈ $6.15 Million |
+37.73% |
| 2016-06-30 | AU$6.31 Million ≈ $4.47 Million |
+15.52% |
| 2015-06-30 | AU$5.46 Million ≈ $3.87 Million |
-43.46% |
| 2014-06-30 | AU$9.66 Million ≈ $6.84 Million |
-32.03% |
| 2013-06-30 | AU$14.22 Million ≈ $10.06 Million |
-8.41% |
| 2012-06-30 | AU$15.52 Million ≈ $10.98 Million |
+107.76% |
| 2011-06-30 | AU$7.47 Million ≈ $5.29 Million |
+7.61% |
| 2010-06-30 | AU$6.94 Million ≈ $4.91 Million |
+6.82% |
| 2009-06-30 | AU$6.50 Million ≈ $4.60 Million |
-46.71% |
| 2008-06-30 | AU$12.20 Million ≈ $8.63 Million |
+219.53% |
| 2007-06-30 | AU$3.82 Million ≈ $2.70 Million |
-10.35% |
| 2006-06-30 | AU$4.26 Million ≈ $3.01 Million |
+7.95% |
| 2005-06-30 | AU$3.94 Million ≈ $2.79 Million |
+201.25% |
| 2004-06-30 | AU$1.31 Million ≈ $926.52K |
-- |
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more